(070) Assessment the Efficacy of Daily Use of Duloxetine in Treatment of Premature Ejaculation: A Prospective Randomized Placebo-Controlled Cross Over Clinical Trial

Abstract Introduction Premature ejaculation is considered to be the most common male sexual disorder, affecting 5% to 40% of sexually active men. Duloxetine is a serotonin and norepinephrine reuptake inhibitor. •It inhibits the reuptake of serotonin and norepinephrine, combining two therapeutic mechanisms in one agent to treat depression and anxiety and also raises dopamine levels. Objective The aim of this study is evaluating the efficacy of “daily” use of Duloxetine in treatment of PE either primary or secondary. Methods •This Randomized Clinical Trial enrolled among (68) Male patients had Premature ejaculation (PE) diagnosed with quantification of the intra-vaginal ejaculation latency time (IELT) less than 2 minutes. •The (68) potent male patients complaining of PE were divided into two groups: - •Intervention arm Group (A): patients with PE either primary or secondary that received (duloxetine 30mg) daily for 1 month. •Control arm Group (B): patients with PE either primary or secondary that they received placebo treatment daily for 1 month Results A total of 68 patients were eligible for inclusion in the current study, they had a mean age of 38.4 ± 6.1 years, secondary premature ejaculation accounted for 91.2% of the included patients. Baseline IIEF-5 showed a median of 24 (range 22–33), median AIPE was 19 (range 8–30), median IELT 60 sec (range 30–120), median Male SQOL 20 (range 15–33). •All participants had a median AIPE was 26 (range 9–34), median IELT 180 sec (range 30–240), median Male SQOL 43 (range 18–55) after being treated with duloxetine. While median AIPE after placebo was 19 (range 8–30), IELT after placebo 60 seconds (30–160), Male SQOL after placebo was 21 (range 16–33). Conclusions •A daily dose of Duloxetine (30 mg) had an effective role in improving premature ejaculation (PE)severity and quality of life either primary or secondary regarding Disclosure No.